Birgit Weynand

Dr. Birgit Weynand

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DLDiether Lambrechts
Diether Lambrechts
EWEls Wauters
Els Wauters
BBBram Boeckx
Bram Boeckx
SASara Aibar
Sara Aibar
DNDavid Nittner
David Nittner
Bernard ThienpontBernard Thienpont
Bernard Thienpont

9 October 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SKSuzanne Kaptein
Suzanne Kaptein
SJSofie Jacobs
Sofie Jacobs
LLLana Langendries
Lana Langendries
LSLaura Seldeslachts
Laura Seldeslachts
SHSebastiaan ter Horst
Sebastiaan ter Horst
Leen DelangLeen Delang
Leen Delang
Significance: The previous lack of consensus around the use of hydroxychloroquine for COVID-19 patients underlines the need to thoroughly assess the in vivo efficacy of drugs against SARS-CoV-2. Small animal infection models, such as the hamster model, have a pivotal place herein. We here show in vivo preclinical results with favipiravir which indicate that antiviral efficacy against SARS-CoV-2 might only be achieved with a very high dose. Hydroxychloroquine, on the other hand, completely lacks antiviral activity, thus providing no scientific basis for its further use in COVID-19 patients. With this study on two key antiviral candidates, we establish the baseline for SARS-CoV-2 antiviral treatment, which will allow us to identify superior antiviral candidates in the near future.

17 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
RBRobbert Boudewijns
Robbert Boudewijns
HTHendrik Jan Thibaut
Hendrik Jan Thibaut
SKSuzanne Kaptein
Suzanne Kaptein
RLRong Li
Rong Li
VVValentijn Vergote
Valentijn Vergote
KDKai Dallmeier
Kai Dallmeier
Emergence of SARS-CoV-2 causing COVID-19 has resulted in hundreds of thousands of deaths. In search for key targets of effective therapeutics, robust animal models mimicking COVID-19 in humans are urgently needed. Here, we show that Syrian hamsters, in contrast to mice, are highly permissive to SARS-CoV-2 and develop bronchopneumonia and strong inflammatory responses in the lungs with neutrophil infiltration and edema, further confirmed as consolidations visualized by micro-CT alike in clinical practice. Moreover, we identify an exuberant innate immune response as key player in pathogenesis, in which STAT2 signaling plays a dual role, driving severe lung injury on the one hand, yet restricting systemic virus dissemination on the other. Our results reveal the importance of STAT2-dependent interferon responses in the pathogenesis and virus control during SARS-CoV-2 infection and may help rationalizing new strategies for the treatment of COVID-19 patients.

12 August 2022 in Science
Verified
Journal Article
Open access
JLJun Siong Low
Jun Siong Low
JJJosipa Jerak
Josipa Jerak
MTM. Alejandra Tortorici
M. Alejandra Tortorici
MMMatthew McCallum
Matthew McCallum
DPDora Pinto
Dora Pinto
FSFederica Sallusto
Federica Sallusto
The coronavirus spike glycoprotein attaches to host receptors and mediates viral fusion. Using a broad screening approach, we isolated seven monoclonal antibodies (mAbs) that bind to all human-infecting coronavirus spike proteins from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune donors. These mAbs recognize the fusion peptide and acquire affinity and breadth through somatic mutations. Despite targeting a conserved motif, only some mAbs show broad neutralizing activity in vitro against alpha- and betacoronaviruses, including animal coronaviruses WIV-1 and PDF-2180. Two selected mAbs also neutralize Omicron BA.1 and BA.2 authentic viruses and reduce viral burden and pathology in vivo. Structural and functional analyses showed that the fusion peptide–specific mAbs bound with different modalities to a cryptic epitope hidden in prefusion stabilized spike, which became exposed upon binding of angiotensin-converting enzyme 2 (ACE2) or ACE2-mimicking mAbs.

1 December 2020 in Nature
Verified
Journal Article
Closed access
PDF file
LSLorena Sanchez-Felipe
Lorena Sanchez-Felipe
TVThomas Vercruysse
Thomas Vercruysse
SSSapna Sharma
Sapna Sharma
JMJi Ma
Ji Ma
VLViktor Lemmens
Viktor Lemmens
KDKai Dallmeier
Kai Dallmeier

20 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
VGVincent Geldhof
Vincent Geldhof
LRLaura P. M. H. de Rooij
Laura P. M. H. de Rooij
LSLiliana Sokol
Liliana Sokol
JAJacob Amersfoort
Jacob Amersfoort
MSMaxim De Schepper
Maxim De Schepper
PCPeter Carmeliet
Peter Carmeliet
Since a detailed inventory of endothelial cell (EC) heterogeneity in breast cancer (BC) is lacking, here we perform single cell RNA-sequencing of 26,515 cells (including 8433 ECs) from 9 BC patients and compare them to published EC taxonomies from lung tumors. Angiogenic ECs are phenotypically similar, while other EC subtypes are different. Predictive interactome analysis reveals known but also previously unreported receptor-ligand interactions between ECs and immune cells, suggesting an involvement of breast EC subtypes in immune responses. We also identify a capillary EC subtype (LIPEC (Lipid Processing EC)), which expresses genes involved in lipid processing that are regulated by PPAR-γ and is more abundant in peri-tumoral breast tissue. Retrospective analysis of 4648 BC patients reveals that treatment with metformin (an indirect PPAR-γ signaling activator) provides long-lasting clinical benefit and is positively associated with LIPEC abundance. Our findings warrant further exploration of this LIPEC/PPAR-γ link for BC treatment.